Julie Ronyak, MD
Internal Medicine · Medina, OHNPI 1801906003
Payments from drug & device makers
Across 118 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$390
- AstraZeneca$375
- AbbVie$297
- Lilly USA, LLC$266
- GSK$89
- Johnson & Johnson$69
- plus $525 from 17 others
What the payments were for
- Food & beverage$2,011100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $390 |
| AstraZeneca | 24 | $375 |
| AbbVie(2 entities) | 15 | $297 |
| Lilly USA, LLC | 16 | $266 |
| GSK | 5 | $89 |
| Johnson & Johnson | 5 | $69 |
| Exact Sciences | 3 | $66 |
| Pfizer | 3 | $57 |
| Novo Nordisk | 4 | $56 |
| Merck | 3 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $29 |
| Novartis | 1 | $28 |
| Boehringer Ingelheim | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
How this compares
$2,011 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $79,331 |
| MounjaroTirzepatide | 52 | $66,189 |
| OzempicSemaglutide | 35 | $51,297 |
| TrulicityDulaglutide | 43 | $50,397 |
| JanuviaSitagliptin Phosphate | 26 | $36,135 |
| XareltoRivaroxaban | 20 | $29,710 |
| Spiriva RespimatTiotropium Bromide | 40 | $27,048 |
| JardianceEmpagliflozin | 21 | $24,443 |
| FarxigaDapagliflozin Propanediol | 15 | $22,424 |
| TradjentaLinagliptin | 18 | $19,359 |
| Nurtec OdtRimegepant Sulfate | 13 | $12,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,299 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $8,748 |
| Praluent PenAlirocumab | 13 | $6,153 |
| Levothyroxine Sodium | 312 | $3,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $266 | $116,58695 claims |
| PfizerEliquis, Nurtec Odt | $57 | $92,12993 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance, Tradjenta, Stiolto Respimat | $25 | $79,59897 claims |
| Novo NordiskOzempic | $56 | $51,29735 claims |
| MerckJanuvia | $38 | $36,13526 claims |
| Johnson & JohnsonXarelto | $69 | $29,71020 claims |
| AstraZenecaFarxiga | $375 | $22,42415 claims |
| GSKTrelegy Ellipta | $89 | $12,29915 claims |
| AbbVieSynthroid | $297 | $3,06151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Medina
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.